Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Civitas Therapeutics Inc.

Division of Acorda Therapeutics Inc.
www.civitastherapeutics.com

Latest From Civitas Therapeutics Inc.

Anatomy Of A Biotech Company: Acorda Gets Dressed For A Second Act

Acorda's rise, fall, and attempt to rise again is a snapshot of the life of a biotech. The company reached the commercial-stage pinnacle with Ampyra, only to eventually see it fall away to patent challenges. Now, after big staff cuts, the company is hoping to prevail in the commercial market again, this time with Inbrija.

Leadership Companies

Anatomy Of A Biotech Company: Acorda Gets Dressed For A Second Act

Acorda's rise, fall, and attempt to rise again is a snapshot of the life of a biotech. The company reached the commercial-stage pinnacle with Ampyra, only to eventually see it fall away to patent challenges. Now, after big staff cuts, the company is hoping to prevail in the commercial market again, this time with Inbrija.

Commercial Companies

Keeping Track: US FDA Refuses To File Acorda, SteadyMed NDAs

Issues involving inspectional readiness and the drug master production record cited in agency's refusal to review Acorda's Inbrija in Parkinson's disease; SteadyMed faces request for additional design verification and validation testing for drug/device combo Trevyent in pulmonary arterial hypertension.

United States FDA

Acorda Investor Scopia Seeks Big Return From Sale Of The Company

Citing recent deals, hedge fund Scopia encouraged Acorda's board on Aug. 7 to pursue a sale, but the company believes its new strategy focused on Parkinson's disease is best for shareholders.

Business Strategies M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Corregidor Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Acorda Therapeutics Inc.
  • Senior Management
  • Mark Iwicki, Pres. & CEO
    Peter Courossi, CFO
    Richard Batycky, PhD, CSO
    Bryan E Stuart, CBO
  • Contact Info
  • Civitas Therapeutics Inc.
    Phone: (617) 660-4110
    190 Everett Ave.
    Chelsea, MA 02150
    USA
UsernamePublicRestriction

Register